Factors affecting the Apgar score of offsprings born to mothers suffering from systemic lupus erythematosus

Hiromi Shimada, MD♭, Tomohiro Kameda, MD, PhD♭, Kenji Kanenishi, MD, PhD♭, Nobuyuki Miyatake, MD, PhD♭, Shusaku Nakashima, MD♭, Risa Wakiya, MD♭, Mikiya Kato, MD♭, Taichi Miyagi, MD♭, Mai Mahmoud Fahmy Mansour, MD♭, Toshiyuki Hata, MD, PhD♭, Norimitsu Kadowaki, MD, PhD♭, Hiroaki Dobashi, MD, PhD♭

Abstract
To reveal which disease activity parameters affect low Apgar scores of newborns, which is considered as a predictive parameter for neurological development.

We examined retrospectively the data from 42 newborns who were delivered from systemic lupus erythematosus (SLE) mothers from 2006 to 2019. We evaluated whether the disease activity parameters, such as the achievement ratio of lupus low disease activity state (LLDAS), SLE disease activities index (SLEDAI), complement level, titer of anti-double stranded DNA (anti-dsDNA) antibody, therapeutic agents were related with low Apgar scores of newborns.

In 42 newborns, adverse pregnancy outcomes, especially preterm birth (16.7%), low birth weight (31.0%) light-for-date (11.9%) were associated with disease activity parameters or prednisolone dose. Apgar scores at 1 minute were related with unachieved LLDAS and the titer of anti-dsDNA antibody at first and third trimester. SLEDAI score and complement level at third trimester, mean prednisolone dose. Apgar scores at 5 minutes were also associated with the titer of anti-dsDNA antibodies at first and third trimester and mean prednisolone dose. Multivariate analysis showed only high titer of anti-dsDNA antibody was significantly associated with low Apgar score at both one minute and 5 minutes.

In our retrospective study, high titer of anti-dsDNA antibodies at first and third trimester was a risk factor for low Apgar scores of newborns born to SLE mothers. We considered that high titer of anti-dsDNA antibody influenced on children neurological development, therefore, there is a need for long-term follow-up study of SLE offsprings.

Abbreviations: anti-dsDNA antibody = anti-double stranded DNA antibody, APO = adverse pregnancy outcome, ASD = autism spectrum disorder, LFD = light-for-date, LLDAS = lupus low disease activity state, SLE = systemic lupus erythematosus, SLEDAI = systemic lupus erythematosus disease activity index.

Keywords: anti-double-stranded DNA antibody, Apgar score, pregnancy, systemic lupus erythematosus

1. Introduction
Systemic lupus erythematosus (SLE) is an autoimmune disease that occurs in women of childbearing age. The disease can vary from mild to life-threatening, with a variety of symptoms including rash, arthritis, anemia, thrombocytopenia, serositis, nephritis, seizures, and psychosis. As the treatment strategy for SLE has improved considerably, more SLE women are able to become mothers. However, SLE women have high risks for adverse pregnancy outcomes (APOs) including preterm birth, intrauterine growth retardation, and pregnancy loss. Previous studies have found that high disease activity, hypocomplementemia, the presence of anti-double stranded DNA (anti-dsDNA) antibodies and anti-phospholipid antibodies, lupus nephritis, and corticosteroid dose were risk factors for APOs.

On the other hand, many SLE women hope healthy growth and development of their children after birth, and short and long-term outcome of children born to SLE mothers is most important issue. However, it remains unclear whether maternal SLE influences their childrens long-term general health and development. Some reports have revealed associations between maternal SLE and/or antiphospholipid syndrome and neurological abnormalities including learning disorders (especially dyslexia) and autism spectrum disorders (ASD) among the children born to SLE.
mothers.[9–12] Vient et al reported that children born to SLE women were more frequently found to have a diagnosis of ASD compared with control (frequency of ASD was 1.4% vs 0.6%).[10] However, it is unknown which factors influence neurological disorders on these children.

Apgar score is used as a common clinical index for assessing neonatal health status soon after birth. It evaluates heart rate, respiration, color, muscle tone, and reflex, and determines whether extra medical care or emergency care is needed. The test is performed at 1 minute and 5 minutes after birth. Apgar score at 5 minutes is demonstrated as newborns neurological development. Several studies have demonstrated associations between low Apgar score and neurological, cognitive, and psychological abnormalities.[13–15] In particular, low Apgar score at 5 minutes has been shown to be associated with increased risks of postnatal mortality, cerebral palsy, seizure, mental retardation, and autism spectrum disorders.[13–17] However, it has never been reported the association between maternal SLE including its disease activity index and low Apgar score. Therefore, we consider it is important to investigate the relationship between Apgar score and maternal SLE and to identify predictive factors for low Apgar score among births from women with SLE.

The aim of our study was to identify the predictive parameters for low Apgar score among newborns who were delivered from SLE mothers in our institution.

2. Material and methods

2.1. Patients and data collection

Our study was retrospective observational study. SLE patients and their newborns were enrolled, who were delivered at Kagawa University Hospital from May 2006 to September 2019. We excluded the case of miscarriage, and all cases of live birth were intended for our study. These patients were diagnosed with SLE according to the 1997 revision of the 1982 American College of Rheumatology criteria for the classification of SLE. We extracted the data on 42 SLE patients who were treated in our institution from preconception counseling to pregnancy and delivery. We investigated these women's clinical background characteristics (age at conception and disease duration defined as the period from disease onset to conception), autoantibody profiles (anti-SS-A/B antibodies, antinuclear antibodies, anti-β2 glycoprotein I antibody and lupus anticoagulant), SLE disease activity scores and their components, therapeutic agents before and during pregnancy. The association between these parameters and pregnancy outcomes, which included gestational weeks at delivery, preterm birth, birth weight, light-for-date (LFD) and Apgar score of newborns, was evaluated. Apgar score was assessed through measures of appearance (color), pulse (heart rate), grimace (reflex), activity (muscle tone), and respiration.[16] Gynecologist or pediatrician scored each index from 0 to 2 and calculated all of these scores. LFD was defined as birth weight of the newborn lower than the 10th percentile.

All data were collected from medical records at Kagawa University Hospital. Disease activity score was calculated using the SLE Disease Activity Index (SLEDAI).[17,18] which is scored from 0 to 105 and includes 24 weighted objective clinical and laboratory variables, for example, neurological dysfunction, arthritis, rash, proteinuria, low complement, and high titer of anti-dsDNA antibodies. In addition, disease activity was also evaluated by lupus low disease activity state (LLDAS), which was defined as SLEDAI-24 ≤ 4 with no activity in major organ systems (renal, central nervous system, cardiopulmonary vasculitis, fever) no hemolytic anemia or gastrointestinal activity,[22] no new lupus disease activity compared with the previous assessment,[19] physician global assessment (scale 0–3) ≤ 1,[20] a current prednisolone dose ≤ 7.5 mg per day, and[23] well tolerated standard maintenance doses of immunosuppressive drugs and approved biologic agents.[24] The components of SLE disease activity score included complement level; C3, C4, and CH50 and the titer of anti-dsDNA antibody. All laboratory tests were performed using standard methods.

Our research was retrospective observational study, therefore, we have never received the ethical approval. We did not obtain patients informed consents, however, we disclosed the information of our research.

2.2. Statistical analysis

Values are presented as mean ± standard deviation for continuous variables and as numbers (percentage) for categorical variables. We investigated the association with univariate and multivariate logistic regression analysis between the Apgar score of newborns and the SLEDAI score, LLDAS achievement, disease activity components, and glucocorticoid dose during pregnancy. Descriptive statistics were compared using the Wilcoxon signed-rank test for continuous variables, and Fishers exact test for categorical variables. The correlation analysis was performed by Spearman Correlation Test. P value of <0.05 was considered significant. We considered parameters with significant differences to be predictive factors. All analyses were conducted using JMP for Mac, Version 13.0.0 (SAS institute, Japan).

3. Results

3.1. Patients characteristics at conception

There were 52 SLE pregnant patients in study period, and 10 cases were miscarriage, which were excluded. Therefore, our study used the data from 42 SLE pregnant patients and their newborns. The patients characteristics at conception are shown in Table 1. The mean age at delivery was 32.2±4.2 years old, and mean disease duration was 10.8±3.3 years. More than half of all cases were positive for anti-SS-A antibody (63.3%) and antiphospholipid antibody (50.0%).

3.2. Disease activity parameters and therapeutic agents

Table 1 also showed disease activity parameters and therapeutic agents. The mean SLEDAI score in the first and third trimesters was 1.7±2.2 and 1.0±1.4, respectively. Fourteen cases (33.3%) had disease flare which was defined as more than 1 increase of SLEDAI score, and mean gestational weeks of disease flare was 14.2±9.8 weeks. Sixteen cases (38.1%) did not achieve LLDAS and 10 cases (23.8%) did not achieve that without glucocorticoid dose at conception. Complement level was normal (C3: 93.1±21.6, C4: 18.7±7.0, CH50: 41.0±9.0), however, the titer of anti-dsDNA antibody was a little high (14.8±40.6). Glucocorticoid was administered in about 80% cases at the conception and during pregnancy. Mean prednisolone dose was 6.7±4.4 mg per day at the conception and 8.2±4.4 mg per day during pregnancy. The mean dose during pregnancy was increased compared with that of conception.
and the others (data not shown).

There were also no significant differences on any disease activity parameters between the cases of hypertensive disorder of pregnancy occurred in 3 (7.1%) cases (at conception) and disease activity parameters, therapeutic agents.

Disease activity parameters 1st trimester (At conception) 3rd trimester

1st trimester (At conception) 3rd trimester

Mean Apgar score at 1 minute 7.8 ± 1.1
Mean Apgar score at 5 minutes 9.0 ± 0.4

Table 1

| Patients characteristics at conception and disease activity parameters, therapeutic agents. | n = 42 |
|---|---|
| Mean age at conception (years old) | 32.2 ± 4.2 |
| Mean disease duration (years) | 10.8 ± 5.3 |
| Nulliparity (n (%)) | 24 (57.1) |
| Frequency of autoantibodies positivity | |
| Anti SS-A antibody (n (%)) | 27 (64.3) |
| Antiphospholipid antibody (n (%)) | 21 (50.0) |

Data are presented as mean ± standard deviation or number (percentage).

Table 2

| Pregnancy outcome. | n = 42 |
|---|---|
| Transvaginal delivery (n (%)) | 32 (76.2) |
| Cesarean section (n (%)) | 10 (23.8) |
| Mean gestational weeks at delivery (weeks) | 37.9 ± 2.7 |
| Preterm birth (n (%)) | 7 (16.7) |
| Hypertensive disorder (n (%)) | 3 (7.1) |
| Mean birth weight (g) | 2753.9 ± 621.5 |
| Low birth weight (< 2500 g) (n (%)) | 13 (31.0) |
| Light-for-date (LFD) (n (%)) | 5 (11.9) |
| Mean Apgar score | |
| at 1 minute | 7.8 ± 1.1 |
| at 5 minutes | 9.0 ± 0.4 |

Data are presented as mean ± standard deviation or number (percentage).

3.3. Adverse pregnancy outcomes is associated with disease activity parameter

Pregnancy outcomes are shown in Table 2. In 42 cases, Cesarean section was performed in 10 cases (23.8%). The mean gestational time was 37.9 ± 2.7 weeks, and preterm birth occurred in seven cases (16.7%). High titer of anti-dsDNA antibody every time (at first or third trimester), and unachieved LLDAS at third trimester were related with preterm birth significantly (P = .04, 0.01, and <0.05, respectively, Supplemental table 1, http://links.lww.com/MD/F74). Hypertensive disorders of pregnancy occurred in 3 cases. There were also no significant differences on any disease activity parameters between the cases of hypertensive disorder and the others (data not shown).

As for the outcomes of newborns, the mean birth weight was 2753.9 ± 621.5 g. Thirteen newborns were low birth weight (less than 2500 g). In their mothers, hypocomplement of C3 every time (at first or third trimester) and CH50 at first trimester, in addition, higher rate of glucocorticoid use were observed (Supplemental Table 2, http://links.lww.com/MD/F73). Five newborns (11.9%) were LFD, and hypocomplement of CH50 at first trimester, and high SLEDAI score at third trimester was detected in LFD mothers (Supplemental Table 3, http://links.lww.com/MD/F74).

3.4. Apgar score is associated with the titer of anti-dsDNA antibody

As for Apgar score of newborns, mean Apgar score at 1 minute and 5 minutes was 7.8 ± 1.1 and 9.0 ± 0.4, respectively. Tables 3 and 4 shows the results of the univariate analysis for Apgar score at 1 minute and 5 minutes. Apgar score at 1 minute was correlated with unachieved LLDAS and the titer of anti-dsDNA antibody at first and third trimester. SLEDAI score, complement level at third trimester, and mean prednisolone dose during pregnancy was also associated with that. Apgar score at 5 minutes was correlated with only the titer of anti-dsDNA antibodies at first and third trimester and mean prednisolone dose during pregnancy. Tables 5 and 6 shows multivariate analysis of relevance to low Apgar score at 1 minute and 5 minutes. We demonstrated that only high titer of anti-dsDNA antibody was significantly associated with low Apgar score at both 1 minute and 5 minutes. In our study, explanatory variable was limited by small number of cases, so that we evaluated with several combinations of variables. Other disease activity index and treatment agent was not associated with Apgar score. In addition, birth weight of newborns was also correlated with Apgar score at both 1 minute and 5 minutes in univariate analysis. However, the titer of anti-dsDNA antibody was more significant association with Apgar score in multivariate analysis (data not shown).

4. Discussion

Our retrospective study identified the association between low Apgar score of newborns and high titer of anti-dsDNA antibodies at both first and third trimester. In the univariate analysis, no achievement of LLDAS and the anti-dsDNA antibody at first and third trimester, SLEDAI score and complement level at third trimester, and mean prednisone dose during pregnancy were significantly related to Apgar score at 1 minute, and the titer of
anti dsDNA antibody at first and third trimester and mean prednisolone dose during pregnancy were also significantly related with Apgar score at 5 minutes. Furthermore, in multivariate analysis, only high titer of anti-dsDNA antibody was significantly associated with low Apgar score at both 1 minute and 5 minutes. Other disease activity parameters were not associated with low Apgar score.

Apgar scores is widely used as a common clinical index for assessing neonatal health status after birth. Especially, Apgar score at 5 minutes is demonstrated as a predictive index for neurological, cognitive, and psychological abnormalities of newborns. In these reports, antiphospholipid and anti-dsDNA antibody was found to be associated with low Apgar score. This might be related with high frequency of neurological disorders such as learning disorders and autism spectrum disorders of SLE offsprings.

Some studies have shown that low Apgar score at 5 minutes has been shown to be associated with increased risks of postnatal mortality, cerebral palsy, seizure, mental retardation, and autism spectrum disorders. In addition, some studies have shown that maternal SLE and/or antiphospholipid syndrome has resulted in low statistical power. Second, because this was a retrospective study, we could not fully exclude selection or information bias, and some cases lacked data such as laboratory findings. Third, this study was conducted in only one expert center.

Table 3

| Disease activity parameters | 1st trimester | 3rd trimester |
|----------------------------|--------------|--------------|
|                            | Correlation coefficient (r) | P value | Correlation coefficient (r) | P value |
| ---------------------------|-----------------|---------|-----------------|---------|
| No achievement of LLDAS†   | .02*            | .02*    | .04*            | .01*    |
| No achievement of LLDAS without glucocorticoid dose‡ | .06 | .01* | .04 | .01* |
| SLEDAI score†              | −0.301         | .06     | −0.577          | <.01*   |
| C3†                        | 0.179          | .28     | 0.436           | <.01*   |
| C4†                        | 0.297          | .07     | 0.283           | .09     |
| CH50‡                      | 0.273          | .10     | 0.427           | .01*    |
| Titer of anti-dsDNA antibody‡ | −0.605   | <.01*  | −0.540          | <.01*   |
| Treatment agents           |                |         |                 |         |
| Mean prednisolone dose during pregnancy§ | −0.509 | <.01* |                 |         |

Table 4

| Disease activity parameters | 1st trimester | 3rd trimester |
|----------------------------|--------------|--------------|
|                            | Correlation coefficient (r) | P value | Correlation coefficient (r) | P value |
| ---------------------------|-----------------|---------|-----------------|---------|
| No achievement of LLDAS†   | .14            | .15     | .26             | .12     |
| No achievement of LLDAS without glucocorticoid dose‡ | .42 | .26 | .26 | .12 |
| SLEDAI score†              | −0.110         | .50     | −0.282          | .07     |
| C3†                        | 0.204          | .21     | 0.235           | .17     |
| C4†                        | 0.229          | .17     | 0.003           | .59     |
| CH50‡                      | 0.273          | .10     | 0.221           | .20     |
| Titer of anti-dsDNA antibody‡ | −0.685 | <.01*  | −0.413          | .01*    |
| Treatment agents           |                |         |                 |         |
| Mean prednisolone dose during pregnancy§ | −0.423 | <.01* |                 |         |

1 Spearman correlation coefficient.
2 Wilcoxon rank sum test.
3 P < .05.
4 anti-dsDNA antibody = anti-double stranded DNA antibody, LLDAS = lupus low disease activity state, SLEDAI = systemic lupus erythematosus disease activity index.
Table 5: Multivariate analysis of relevance to low Apgar score at 1 minute.

| Trimester | Standard β | P value |
|-----------|------------|---------|
| 1st trimester | | |
| SLEDS without glucocorticoid dose | -0.110 | .33 |
| C3 | -0.043 | .60 |
| Titer of anti-dsDNA antibody | -0.773 | <.01 |
| R²=0.659, P<.01 |
| 2nd trimester | | |
| C3 | 0.104 | .55 |
| CH50 | 0.173 | .32 |
| Titer of anti-dsDNA antibody | -0.069 | <.01 |
| R²=0.652, P<.01 |

Multi logistic regression test. Anti-dsDNA antibody = anti-double stranded DNA antibody, LDAI = lupus dsDNA. LDAI = lupus disease activity state.

Table 6: Multivariate analysis of relevance to low Apgar score at 5 minutes.

| Trimester | Standard β | P value |
|-----------|------------|---------|
| 1st trimester | | |
| SLEDAI score | 0.203 | .16 |
| CH50 | 0.195 | .16 |
| Titer of anti-dsDNA antibody | -0.742 | <.01 |
| R²=0.571, P<.01 |
| 2nd trimester | | |
| C4 | -0.135 | .43 |
| CH50 | 0.146 | .39 |
| Titer of anti-dsDNA antibody | -0.582 | <.01 |
| R²=0.356, P<.01 |

Multi logistic regression test. Anti-dsDNA antibody = anti-double stranded DNA antibody, LDAI = lupus disease activity state.

 institution; therefore, we might have collected data on patients with relatively high levels of disease activity and high risks for pregnancy.

5. Conclusion

In our retrospective study, low Apgar scores of newborns who were delivered from SLE mothers were associated with high titer of anti-dsDNA antibodies at first and second trimester in both univariate and multivariate analysis. Thus, high titer of anti-dsDNA antibodies might be a predictive factor for low Apgar scores which are associated with neurological development of newborns. In preconception counseling, it is important for our rheumatologists to explain these predictive factors clearly to SLE patients who hope to conceive. It will be beneficial for both SLE mothers and their newborns to manage these factors carefully before and during pregnancy. Furthermore, there is a need for long-term follow-up studies focusing on the neurological development of children born to SLE mothers.

Acknowledgments

We thank Jennifer Barrett, PhD, from Edanz Group (www.edanzediting.com/ac) for editing a draft of this manuscript.

Author contributions

Conceptualization: Hiroaki Dobashi.
Data curation: Hiromi Shimada, Nobuyuki Miyatake.

Formal analysis: Hiromi Shimada, Nobuyuki Miyatake.
Investigation: Hiromi Shimada.
Methodology: Hiromi Shimada, Kenji Kanenishi, Nobuyuki Miyatake, Hiroaki Dobashi.
Supervision: Tomohiro Kameda, Toshiyuki Hata, Norimitsu Kodowski, Hiroaki Dobashi.
Validation: Kenji Kanenishi, Nobuyuki Miyatake, Norimitsu Kodowski, Hiroaki Dobashi.
Visualization: Nobuyuki Miyatake.
Writing – original draft: Hiromi Shimada.
Writing – review & editing: Tomohiro Kameda, Kenji Kanenishi, Shusaku Nakashima, Risa Wakiya, Mikiya Kato, Taichi Miyagi, Mai Mahmoud Fahmry Mansour, Hiroaki Dobashi.

References

[1] Clowse ME, Jamison M, Myers E, et al. A national study of the complications of lupus in pregnancy. Am J Obstet Gynecol 2008;199: 127e1–6.
[2] Bundhun PK, Soogund MZ, Haffong F. Impact of systemic lupus erythematosus on maternal and fetal outcomes following pregnancy: a meta-analysis of studies published between years 2001–2016. J Autoimmun 2017;79:17–27.
[3] He WR, Wei H. Maternal and fetal complications associated with systemic lupus erythematosus: an updated meta-analysis of the most recent studies (2017–2019). Medicine 2020;99:e19797.
[4] Buyon JP, Kim MY, Guerra MM, et al. Predictors of pregnancy outcomes in patients with lupus: a cohort study. Ann Intern Med 2015;163:153–63.
[5] Smyth A, Oliveira GH, Lahr BD, et al. A systemic review and meta-analysis of pregnancy outcomes in patients with systemic lupus erythematosus and lupus nephritis. Clin J Am Nephrol 2010;5:2060–8.
[6] Zhan Z, Yang Y, Zhan Y, et al. Fetal outcomes and associated factors of adverse outcomes of pregnancy in southern Chinese women with systemic lupus erythematosus. PLoS One 2017;12:e0176437.
[7] Deguchi M, Maesawa Y, Kubota S, et al. Factors associated with adverse pregnancy outcomes in women with systemic lupus erythematosus. J Reprod Immunol 2018;125:39–44.
[8] Clowse ME, Magder LS, Petri M. The clinical utility of measuring complement and anti-dsDNA antibodies during pregnancy in patients with systemic lupus erythematosus. J Rheumatol 2011;38: 1012–6.
[9] Nacinovich R, Galli J, Bomba M, et al. Neuropsychological development of children born to patients with antiphospholipid syndrome. Arthritis Rheum 2008;59:345–51.
[10] Vient E, Pineau CA, Clarke AE, et al. Increased risk of autism spectrum disorders in children born to women with systemic lupus erythematosus: results from a large population-based cohort. Arthritis Rheumatol 2015;67:3201–8.
[11] Nalli C, Iodice A, Andreoli L, et al. Long-term neurodevelopmental outcome of children born to prospectively followed pregnancies of women with systemic lupus erythematosus and/or antiphospholipid syndrome. Lupus 2017;26:532–8.
[12] Yousef Yengej FA, van Royen-Kerkhof A, Derksen RHWM, et al. The development of offspring from mothers with systemic lupus erythematosus: a systematic review. Autoimmun Rev 2017;16: 701–11.
[13] Gampel SB, Nomura Y. Short and long-term effects of compromised birth weight, head circumference, and Apgar scores on neuropsychological development. J Psychol Abnorm Child 2011;4:3127.
[14] Thorngren-Jerneck K, Herbst A. Low 5-minute Apgar score: a population-based register study of 1 million term births. Obstet Gynecol 2001;98:65–70.
[15] Casey BM, McIntire DD, Leveno KJ. The continuing value of the Apgar score for the assessment of newborn infants. N Engl J Med 2001;344:467–71.
[16] Modabbernia A, Sandin S, Gross R, et al. Apgar score and risk of autism. Eur J Epidemiol 2018;33:10. 1007/s10654-018-0445-1.
[17] Polo-Kantola P, Lamps KM, Hinkka-Yli-Salomaki S, et al. Obstetric risk factors and autism spectrum disorders in Finland. J Pediatr 2014;164:358–65.
[18] American Academy of Pediatrics Committee on Fetus NewbornThe Apgar score. Pediatrics 2015;136:819–22.
[19] Bombardier C, Gladman DD, Urowitz MB, et al. Derivation of the SLEDAI: a disease activity index for lupus patients. The committee on Prognosis Studies in SLE. Arthritis Rheum 1992;35: 630–40.
[20] Griffiths B, Mosca M, Gordon C. Assessment of patients with systemic lupus erythematosus and the use of lupus disease activity indices. Best Pract Res Clin Rheumatol 2005;19:658–708.
[21] Franklyn K, Lau CS, Navarra SV, et al. Definition and initial validation of a Lupus Low Disease Activity State (LLDAS). Ann Rheum Dis 2016;75:1615–21.